<p>Erasca, Inc.（纳斯达克代码：ERAS - 免费报告）- HC Wainwright 的股票研究分析师在 1 月 13 日星期二发布的报告中上调了对 Erasca 2027 财年的盈利预期。HC Wainwright 的分析师 A. Maldonado 现在预测该公司将在该年度每股盈利（$0.40），高于之前的预测（$0.44）。HC Wainwright 目前对该股票给予 “买入” 评级，目标价为 11.00 美元。市场普遍预计 Erasca 当前全年的每股盈利为（$0.73）。HC Wainwright 还对 Erasca 2028 财年的盈利预期为每股（$0.27），2029 财年的盈利为每股（$0.09），2030 财年的盈利为每股（$0.02）。</p>
<p>Erasca（纳斯达克代码：ERAS - 获取免费报告）最近在 11 月 12 日星期三发布了其盈利结果。该公司报告季度每股盈利（EPS）为（$0.11），符合分析师的普遍预期（$0.11）。</p>
<p>其他几家研究公司也最近对 ERAS 发表了评论。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Erasca 股票的 “卖出（d-）” 评级。瑞穗证券在 12 月 9 日星期二将 Erasca 的目标价从 4.00 美元上调至 5.00 美元，并给予该公司 “跑赢大盘” 的评级。Piper Sandler 在 1 月 7 日星期三开始对 Erasca 进行覆盖。他们为该公司设定了 “增持” 评级和 5.00 美元的目标价。Guggenheim 在 11 月 14 日星期五将 Erasca 股票的目标价从 3.00 美元上调至 5.00 美元，并给予该股票 “买入” 评级。最后，摩根士丹利在 1 月 8 日星期四的研究报告中为 Erasca 股票设定了 4.00 美元的目标价。七位分析师对该股票给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 5.44 美元。</p>
<p><strong>获取我们对 Erasca 的最新股票分析</strong></p>
<h2>Erasca 股票表现</h2>
<p>ERAS 股票在星期四开盘价为 8.23 美元。Erasca 的一年低点为 1.01 美元，一年高点为 8.45 美元。该股票的 50 日移动平均线为 3.58 美元，200 日移动平均线为 2.42 美元。该股票的市值为 23.4 亿美元，市盈率为 -18.18，贝塔值为 1.15。</p>
<h2>对 Erasca 的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近修改了对该股票的持有情况。Frazier Life Sciences Management L.P. 在第二季度将其在 Erasca 的持股增加了 0.7%。Frazier Life Sciences Management L.P. 目前拥有 22,729,436 股该公司的股票，价值 28,866,000 美元，在此期间又购买了 153,585 股。VR Adviser LLC 在第二季度将其在 Erasca 的持股增加了 10.1%。VR Adviser LLC 目前拥有 17,857,083 股该公司的股票，价值 22,678,000 美元，在此期间又购买了 1,640,867 股。Paradigm Biocapital Advisors LP 在第三季度将其在 Erasca 的持股增加了 13.9%。Paradigm Biocapital Advisors LP 目前拥有 13,560,017 股该公司的股票，价值 29,561,000 美元，在此期间又购买了 1,652,835 股。Vanguard Group Inc. 在第三季度将其在 Erasca 的持股增加了 0.9%。Vanguard Group Inc. 目前拥有 12,811,832 股该公司的股票，价值 27,930,000 美元，在上个季度又购买了 116,235 股。最后，Vivo Capital LLC 在第三季度将其在 Erasca 的持股增加了 37.2%。Vivo Capital LLC 目前拥有 9,273,428 股该公司的股票，价值 20,216,000 美元，在此期间又收购了 2,516,672 股。67.78% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>Erasca 的内部活动</h2>
<p>在其他新闻中，首席法律顾问 Ebun Garner 在 1 月 7 日星期三出售了 120,000 股公司的股票。该股票以平均价格 5.59 美元出售，总交易额为 670,800.00 美元。出售完成后，首席法律顾问直接持有 25,076 股公司的股票，价值 140,174.84 美元。此交易代表其持股减少了 82.72%。该交易已在与 SEC 的法律文件中披露，相关文件可通过此链接获取。公司内部人士持有公司股票的 14.40%。</p>
<h2>Erasca 公司简介</h2>
<p>（获取免费报告）</p>
<p>Erasca, Inc 是一家临床阶段的生物制药公司，致力于为癌症患者发现和开发精准医疗。该公司专注于小分子治疗药物，针对肿瘤生长和存活中涉及的关键信号通路，主要强调 MAPK 通路的抑制剂。Erasca 的方法旨在提供口服的靶向疗法，解决肿瘤基因驱动和免疫肿瘤学的适应症，旨在改善满足医疗需求的患者的治疗结果。</p>
<p>Erasca 的产品线包括多个开发候选药物，包括旨在干扰癌细胞信号传导关键节点的小分子抑制剂。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Erasca</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的一次</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVJBUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVJBUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Erasca 吗？</h2>
<p>在您考虑 Erasca 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Erasca 并不在名单上。</p>
<p>虽然 Erasca 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ERAS

<p>Erasca, Inc.（纳斯达克代码：ERAS）在 HC Wainwright 的调研中，其 2027 财年的盈利预测被上调，现预计每股亏损为（$0.40），之前为（$0.44）。该公司维持 “买入” 评级，目标价为$11.00。当前全年的共识盈利预期为每股亏损（$0.73）。其他分析师的评级各不相同，整体评级为 “适度买入”，目标价为$5.44。Erasca 的股票开盘价为$8.23，市值为 23.4 亿美元，机构持股比例显著</p>

<p>Erasca, Inc. (NASDAQ:ERAS - Free Report) - Equities research analysts at HC Wainwright upped their FY2027 earnings estimates for shares of Erasca in a report issued on Tuesday, January 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.40) per share for the year, up from their previous estimate of ($0.44). HC Wainwright currently has a &#34;Buy&#34; rating and a $11.00 target price on the stock. The consensus estimate for Erasca's current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Erasca's FY2028 earnings at ($0.27) EPS, FY2029 earnings at ($0.09) EPS and FY2030 earnings at ($0.02) EPS.</p>
<div class="lb-trans"><p>Erasca, Inc.（纳斯达克代码：ERAS - 免费报告）- HC Wainwright 的股票研究分析师在 1 月 13 日星期二发布的报告中上调了对 Erasca 2027 财年的盈利预期。HC Wainwright 的分析师 A. Maldonado 现在预测该公司将在该年度每股盈利（$0.40），高于之前的预测（$0.44）。HC Wainwright 目前对该股票给予 “买入” 评级，目标价为 11.00 美元。市场普遍预计 Erasca 当前全年的每股盈利为（$0.73）。HC Wainwright 还对 Erasca 2028 财年的盈利预期为每股（$0.27），2029 财年的盈利为每股（$0.09），2030 财年的盈利为每股（$0.02）。</p>
</div><p>Erasca (NASDAQ:ERAS - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.11).</p>
<div class="lb-trans"><p>Erasca（纳斯达克代码：ERAS - 获取免费报告）最近在 11 月 12 日星期三发布了其盈利结果。该公司报告季度每股盈利（EPS）为（$0.11），符合分析师的普遍预期（$0.11）。</p>
</div><p>Several other research firms have also recently commented on ERAS. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Erasca in a research report on Wednesday, October 8th. Mizuho raised their target price on Erasca from $4.00 to $5.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, December 9th. Piper Sandler started coverage on Erasca in a research report on Wednesday, January 7th. They set an &#34;overweight&#34; rating and a $5.00 price target for the company. Guggenheim upped their price objective on shares of Erasca from $3.00 to $5.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, November 14th. Finally, Morgan Stanley set a $4.00 target price on shares of Erasca in a research note on Thursday, January 8th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $5.44.</p>
<div class="lb-trans"><p>其他几家研究公司也最近对 ERAS 发表了评论。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Erasca 股票的 “卖出（d-）” 评级。瑞穗证券在 12 月 9 日星期二将 Erasca 的目标价从 4.00 美元上调至 5.00 美元，并给予该公司 “跑赢大盘” 的评级。Piper Sandler 在 1 月 7 日星期三开始对 Erasca 进行覆盖。他们为该公司设定了 “增持” 评级和 5.00 美元的目标价。Guggenheim 在 11 月 14 日星期五将 Erasca 股票的目标价从 3.00 美元上调至 5.00 美元，并给予该股票 “买入” 评级。最后，摩根士丹利在 1 月 8 日星期四的研究报告中为 Erasca 股票设定了 4.00 美元的目标价。七位分析师对该股票给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 5.44 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Erasca</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Erasca 的最新股票分析</strong></p>
</div><h2>Erasca Stock Performance</h2>
<div class="lb-trans"><h2>Erasca 股票表现</h2>
</div><p>ERAS stock opened at $8.23 on Thursday. Erasca has a 1 year low of $1.01 and a 1 year high of $8.45. The stock's fifty day moving average is $3.58 and its two-hundred day moving average is $2.42. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of -18.18 and a beta of 1.15.</p>
<div class="lb-trans"><p>ERAS 股票在星期四开盘价为 8.23 美元。Erasca 的一年低点为 1.01 美元，一年高点为 8.45 美元。该股票的 50 日移动平均线为 3.58 美元，200 日移动平均线为 2.42 美元。该股票的市值为 23.4 亿美元，市盈率为 -18.18，贝塔值为 1.15。</p>
</div><h2>Hedge Funds Weigh In On Erasca</h2>
<div class="lb-trans"><h2>对 Erasca 的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. boosted its position in Erasca by 0.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 22,729,436 shares of the company's stock worth $28,866,000 after purchasing an additional 153,585 shares during the period. VR Adviser LLC increased its holdings in Erasca by 10.1% in the 2nd quarter. VR Adviser LLC now owns 17,857,083 shares of the company's stock valued at $22,678,000 after buying an additional 1,640,867 shares during the period. Paradigm Biocapital Advisors LP lifted its stake in Erasca by 13.9% during the third quarter. Paradigm Biocapital Advisors LP now owns 13,560,017 shares of the company's stock worth $29,561,000 after purchasing an additional 1,652,835 shares during the period. Vanguard Group Inc. boosted its holdings in Erasca by 0.9% during the third quarter. Vanguard Group Inc. now owns 12,811,832 shares of the company's stock valued at $27,930,000 after purchasing an additional 116,235 shares in the last quarter. Finally, Vivo Capital LLC grew its position in Erasca by 37.2% in the third quarter. Vivo Capital LLC now owns 9,273,428 shares of the company's stock valued at $20,216,000 after acquiring an additional 2,516,672 shares during the period. 67.78% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近修改了对该股票的持有情况。Frazier Life Sciences Management L.P. 在第二季度将其在 Erasca 的持股增加了 0.7%。Frazier Life Sciences Management L.P. 目前拥有 22,729,436 股该公司的股票，价值 28,866,000 美元，在此期间又购买了 153,585 股。VR Adviser LLC 在第二季度将其在 Erasca 的持股增加了 10.1%。VR Adviser LLC 目前拥有 17,857,083 股该公司的股票，价值 22,678,000 美元，在此期间又购买了 1,640,867 股。Paradigm Biocapital Advisors LP 在第三季度将其在 Erasca 的持股增加了 13.9%。Paradigm Biocapital Advisors LP 目前拥有 13,560,017 股该公司的股票，价值 29,561,000 美元，在此期间又购买了 1,652,835 股。Vanguard Group Inc. 在第三季度将其在 Erasca 的持股增加了 0.9%。Vanguard Group Inc. 目前拥有 12,811,832 股该公司的股票，价值 27,930,000 美元，在上个季度又购买了 116,235 股。最后，Vivo Capital LLC 在第三季度将其在 Erasca 的持股增加了 37.2%。Vivo Capital LLC 目前拥有 9,273,428 股该公司的股票，价值 20,216,000 美元，在此期间又收购了 2,516,672 股。67.78% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>Insider Activity at Erasca</h2>
<div class="lb-trans"><h2>Erasca 的内部活动</h2>
</div><p>In other news, General Counsel Ebun Garner sold 120,000 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $5.59, for a total transaction of $670,800.00. Following the completion of the sale, the general counsel directly owned 25,076 shares of the company's stock, valued at $140,174.84. This trade represents a 82.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 14.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席法律顾问 Ebun Garner 在 1 月 7 日星期三出售了 120,000 股公司的股票。该股票以平均价格 5.59 美元出售，总交易额为 670,800.00 美元。出售完成后，首席法律顾问直接持有 25,076 股公司的股票，价值 140,174.84 美元。此交易代表其持股减少了 82.72%。该交易已在与 SEC 的法律文件中披露，相关文件可通过此链接获取。公司内部人士持有公司股票的 14.40%。</p>
</div><h2>Erasca Company Profile</h2>
<div class="lb-trans"><h2>Erasca 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca's approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.</p>
<div class="lb-trans"><p>Erasca, Inc 是一家临床阶段的生物制药公司，致力于为癌症患者发现和开发精准医疗。该公司专注于小分子治疗药物，针对肿瘤生长和存活中涉及的关键信号通路，主要强调 MAPK 通路的抑制剂。Erasca 的方法旨在提供口服的靶向疗法，解决肿瘤基因驱动和免疫肿瘤学的适应症，旨在改善满足医疗需求的患者的治疗结果。</p>
</div><p>Erasca's pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.</p>
<div class="lb-trans"><p>Erasca 的产品线包括多个开发候选药物，包括旨在干扰癌细胞信号传导关键节点的小分子抑制剂。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Erasca</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>First Time Since 2007: All Warnings Active</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Erasca</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的一次</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVJBUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ERAS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Erasca Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Erasca 吗？</h2>
</div><p>Before you consider Erasca, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Erasca 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Erasca 并不在名单上。</p>
</div><p>While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Erasca 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 发布了 Erasca 的 2027 财年盈利预测